View ValuationDermapharm Holding 将来の成長Future 基準チェック /16Dermapharm Holding利益と収益がそれぞれ年間6.9%と3.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に18.1% 7.5%なると予測されています。主要情報6.9%収益成長率7.46%EPS成長率Pharmaceuticals 収益成長12.1%収益成長率3.7%将来の株主資本利益率18.12%アナリストカバレッジGood最終更新日03 Jun 2026今後の成長に関する最新情報お知らせ • Jun 28Dermapharm Holding Se Confirms Earnings Guidance for 2026Dermapharm Holding SE confirmed earnings guidance for 2026. The company expects consolidated revenue of between EUR 1,182 million and EUR 1,218 million.すべての更新を表示Recent updatesお知らせ • Jun 28Dermapharm Holding Se Confirms Earnings Guidance for 2026Dermapharm Holding SE confirmed earnings guidance for 2026. The company expects consolidated revenue of between EUR 1,182 million and EUR 1,218 million.お知らせ • May 19Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026, at 10:00 W. Europe Standard Time.お知らせ • Apr 01Dermapharm Holding SE announces Annual dividend, payable on July 01, 2026Dermapharm Holding SE announced Annual dividend of EUR 0.8800 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.お知らせ • Mar 11Dermapharm Holding SE (XTRA:DMP) announces an Equity Buyback for 4,300,000 shares, representing 7.99% for €180.6 million.Dermapharm Holding SE (XTRA:DMP) announces a share repurchase program. Under the program, the company will repurchase up to 4,300,000 shares, representing 7.99% of the share capital of the Company. The shares will be repurchased at a price of €42 per share. The repurchased shares are intended to be cancelled. If more than 4,300,000 shares are tendered for repurchase into the offer, acceptances will be taken into account on a pro-rata basis in the ratio of 4,300,000 shares to the total number of shares tendered for repurchase by the shareholders. The offer ends, subject to an extension by the company, on March 24, 2026.お知らせ • Nov 19+ 1 more updateDermapharm Holding SE to Report First Half, 2026 Results on Aug 11, 2026Dermapharm Holding SE announced that they will report first half, 2026 results on Aug 11, 2026お知らせ • Nov 13+ 3 more updatesDermapharm Holding SE to Report Fiscal Year 2025 Results on Mar 31, 2026Dermapharm Holding SE announced that they will report fiscal year 2025 results on Mar 31, 2026お知らせ • Jun 28Dermapharm Holding SE Approves Annual DividendDermapharm Holding SE at its Annual General Meeting held on 26 June 2025, acted on the recommendation of the Board of Management and the Supervisory Board to distribute a dividend of EUR 0.90 per share carrying dividend rights. The total distribution amounts to EUR 48.5 million, representing a distribution ratio of approximately 43% of the consolidated net profit eligible for distribution.お知らせ • May 16Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025, at 10:00 W. Europe Standard Time.お知らせ • Jan 02Dermapharm Holding SE to Report Fiscal Year 2024 Results on Mar 14, 2025Dermapharm Holding SE announced that they will report fiscal year 2024 results on Mar 14, 2025お知らせ • May 09Dermapharm Holding SE to Report Q1, 2024 Results on May 15, 2024Dermapharm Holding SE announced that they will report Q1, 2024 results on May 15, 2024お知らせ • Mar 28Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024.お知らせ • Mar 14Dermapharm Holding SE to Report Fiscal Year 2023 Results on Mar 28, 2024Dermapharm Holding SE announced that they will report fiscal year 2023 results on Mar 28, 2024Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €45.46, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €73.48 per share.Reported Earnings • Mar 31Full year 2022 earnings released: EPS: €2.49 (vs €3.89 in FY 2021)Full year 2022 results: EPS: €2.49 (down from €3.89 in FY 2021). Revenue: €1.04b (up 8.4% from FY 2021). Net income: €134.2m (down 36% from FY 2021). Profit margin: 13% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €36.74, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 14x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 2.6% over the past three years.Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improved over the past weekAfter last week's 18% share price gain to €44.92, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 11x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 27% over the past three years.Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: €0.98 (vs €1.15 in 3Q 2021)Third quarter 2022 results: EPS: €0.98 (down from €1.15 in 3Q 2021). Revenue: €277.8m (up 13% from 3Q 2021). Net income: €52.5m (down 15% from 3Q 2021). Profit margin: 19% (down from 25% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Sep 17Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to €37.52, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 13x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 21% over the past three years.Reported Earnings • Sep 09Second quarter 2022 earnings released: EPS: €0.27 (vs €0.74 in 2Q 2021)Second quarter 2022 results: EPS: €0.27 (down from €0.74 in 2Q 2021). Revenue: €246.2m (up 12% from 2Q 2021). Net income: €14.5m (down 64% from 2Q 2021). Profit margin: 5.9% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 6.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • May 26Upcoming dividend of €2.17 per shareEligible shareholders must have bought the stock before 02 June 2022. Payment date: 06 June 2022. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 4.6%. Lower than top quartile of British dividend payers (4.8%). Higher than average of industry peers (2.8%).Reported Earnings • May 19First quarter 2022 earnings released: EPS: €0.69 (vs €0.67 in 1Q 2021)First quarter 2022 results: EPS: €0.69 (up from €0.67 in 1Q 2021). Revenue: €239.1m (up 11% from 1Q 2021). Net income: €37.4m (up 2.9% from 1Q 2021). Profit margin: 16% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.8%, compared to a 5.3% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 14Full year 2021 earnings released: EPS: €3.89 (vs €1.59 in FY 2020)Full year 2021 results: EPS: €3.89 (up from €1.59 in FY 2020). Revenue: €960.1m (up 19% from FY 2020). Net income: €209.6m (up 144% from FY 2020). Profit margin: 22% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 10%, compared to a 13% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS €1.15 (vs €0.42 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €264.5m (up 31% from 3Q 2020). Net income: €61.8m (up 173% from 3Q 2020). Profit margin: 23% (up from 11% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Sep 08Second quarter 2021 earnings released: EPS €0.74 (vs €0.22 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €219.1m (up 16% from 2Q 2020). Net income: €39.8m (up 233% from 2Q 2020). Profit margin: 18% (up from 6.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Jun 17Upcoming dividend of €0.88 per shareEligible shareholders must have bought the stock before 24 June 2021. Payment date: 28 June 2021. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (4.0%). Lower than average of industry peers (3.6%).Reported Earnings • May 21First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €218.0m (up 11% from 1Q 2020). Net income: €36.3m (up 36% from 1Q 2020). Profit margin: 17% (up from 14% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improved over the past weekAfter last week's 21% share price gain to €74.65, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 24x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 89% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €81.84 per share.Reported Earnings • Apr 16Full year 2020 earnings released: EPS €1.59 (vs €1.43 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €820.5m (up 15% from FY 2019). Net income: €85.8m (up 11% from FY 2019). Profit margin: 11% (in line with FY 2019).Valuation Update With 7 Day Price Move • Mar 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to €64.69, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 25x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 83% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €81.89 per share.Is New 90 Day High Low • Feb 05New 90-day high: €60.89The company is up 32% from its price of €46.10 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €67.45 per share.Is New 90 Day High Low • Dec 29New 90-day high: €57.29The company is up 26% from its price of €45.54 on 30 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €67.08 per share.Is New 90 Day High Low • Dec 01New 90-day high: €55.96The company is up 22% from its price of €45.82 on 02 September 2020. The British market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €57.89 per share.業績と収益の成長予測BATS-CHIXE:DMPD - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,299171186254512/31/20271,254155177241612/31/20261,20913917824163/31/20261,182144241285N/A12/31/20251,178132187229N/A9/30/20251,174116164207N/A6/30/20251,191107175216N/A3/31/20251,199104131173N/A12/31/20241,195114163201N/A9/30/20241,17491157197N/A6/30/20241,14783146187N/A3/31/20241,12957137179N/A12/31/20231,15162178219N/A9/30/20231,17295240279N/A6/30/20231,151123267304N/A3/31/20231,128146287323N/A12/31/20221,041134250289N/A9/30/20221,024176222269N/A6/30/20221,004185191249N/A3/31/2022980211190252N/A12/31/2021960210189250N/A9/30/2021902162153209N/A6/30/2021858123115164N/A3/31/20218289596139N/A12/31/20208088690131N/A9/30/20207758060104N/A6/30/2020760775897N/A3/31/20207438569114N/A12/31/201971477N/A101N/A9/30/201967473N/A90N/A6/30/201963977N/A109N/A3/31/201961173N/A115N/A12/31/201858475N/A159N/A9/30/201855875N/A165N/A6/30/201852576N/A137N/A3/31/201849879N/A120N/A12/31/201748078N/A87N/A9/30/201748684N/A84N/A12/31/201645577N/A77N/A12/31/201539613N/A40N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: DMPDの予測収益成長率 (年間6.9% ) は 貯蓄率 ( 3.4% ) を上回っています。収益対市場: DMPDの収益 ( 6.9% ) UK市場 ( 11.6% ) よりも低い成長が予測されています。高成長収益: DMPDの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: DMPDの収益 ( 3.7% ) UK市場 ( 4% ) よりも低い成長が予測されています。高い収益成長: DMPDの収益 ( 3.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: DMPDの 自己資本利益率 は、3年後には低くなると予測されています ( 18.1 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/21 20:47終値2026/04/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Dermapharm Holding SE 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Gerhard OrgonasBerenbergFabian PiastaJefferies LLCMartin ComtesseJefferies LLC9 その他のアナリストを表示
お知らせ • Jun 28Dermapharm Holding Se Confirms Earnings Guidance for 2026Dermapharm Holding SE confirmed earnings guidance for 2026. The company expects consolidated revenue of between EUR 1,182 million and EUR 1,218 million.
お知らせ • Jun 28Dermapharm Holding Se Confirms Earnings Guidance for 2026Dermapharm Holding SE confirmed earnings guidance for 2026. The company expects consolidated revenue of between EUR 1,182 million and EUR 1,218 million.
お知らせ • May 19Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026, at 10:00 W. Europe Standard Time.
お知らせ • Apr 01Dermapharm Holding SE announces Annual dividend, payable on July 01, 2026Dermapharm Holding SE announced Annual dividend of EUR 0.8800 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.
お知らせ • Mar 11Dermapharm Holding SE (XTRA:DMP) announces an Equity Buyback for 4,300,000 shares, representing 7.99% for €180.6 million.Dermapharm Holding SE (XTRA:DMP) announces a share repurchase program. Under the program, the company will repurchase up to 4,300,000 shares, representing 7.99% of the share capital of the Company. The shares will be repurchased at a price of €42 per share. The repurchased shares are intended to be cancelled. If more than 4,300,000 shares are tendered for repurchase into the offer, acceptances will be taken into account on a pro-rata basis in the ratio of 4,300,000 shares to the total number of shares tendered for repurchase by the shareholders. The offer ends, subject to an extension by the company, on March 24, 2026.
お知らせ • Nov 19+ 1 more updateDermapharm Holding SE to Report First Half, 2026 Results on Aug 11, 2026Dermapharm Holding SE announced that they will report first half, 2026 results on Aug 11, 2026
お知らせ • Nov 13+ 3 more updatesDermapharm Holding SE to Report Fiscal Year 2025 Results on Mar 31, 2026Dermapharm Holding SE announced that they will report fiscal year 2025 results on Mar 31, 2026
お知らせ • Jun 28Dermapharm Holding SE Approves Annual DividendDermapharm Holding SE at its Annual General Meeting held on 26 June 2025, acted on the recommendation of the Board of Management and the Supervisory Board to distribute a dividend of EUR 0.90 per share carrying dividend rights. The total distribution amounts to EUR 48.5 million, representing a distribution ratio of approximately 43% of the consolidated net profit eligible for distribution.
お知らせ • May 16Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Jan 02Dermapharm Holding SE to Report Fiscal Year 2024 Results on Mar 14, 2025Dermapharm Holding SE announced that they will report fiscal year 2024 results on Mar 14, 2025
お知らせ • May 09Dermapharm Holding SE to Report Q1, 2024 Results on May 15, 2024Dermapharm Holding SE announced that they will report Q1, 2024 results on May 15, 2024
お知らせ • Mar 28Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024.
お知らせ • Mar 14Dermapharm Holding SE to Report Fiscal Year 2023 Results on Mar 28, 2024Dermapharm Holding SE announced that they will report fiscal year 2023 results on Mar 28, 2024
Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €45.46, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €73.48 per share.
Reported Earnings • Mar 31Full year 2022 earnings released: EPS: €2.49 (vs €3.89 in FY 2021)Full year 2022 results: EPS: €2.49 (down from €3.89 in FY 2021). Revenue: €1.04b (up 8.4% from FY 2021). Net income: €134.2m (down 36% from FY 2021). Profit margin: 13% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €36.74, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 14x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 2.6% over the past three years.
Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improved over the past weekAfter last week's 18% share price gain to €44.92, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 11x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 27% over the past three years.
Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: €0.98 (vs €1.15 in 3Q 2021)Third quarter 2022 results: EPS: €0.98 (down from €1.15 in 3Q 2021). Revenue: €277.8m (up 13% from 3Q 2021). Net income: €52.5m (down 15% from 3Q 2021). Profit margin: 19% (down from 25% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Sep 17Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to €37.52, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 13x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 21% over the past three years.
Reported Earnings • Sep 09Second quarter 2022 earnings released: EPS: €0.27 (vs €0.74 in 2Q 2021)Second quarter 2022 results: EPS: €0.27 (down from €0.74 in 2Q 2021). Revenue: €246.2m (up 12% from 2Q 2021). Net income: €14.5m (down 64% from 2Q 2021). Profit margin: 5.9% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 6.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • May 26Upcoming dividend of €2.17 per shareEligible shareholders must have bought the stock before 02 June 2022. Payment date: 06 June 2022. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 4.6%. Lower than top quartile of British dividend payers (4.8%). Higher than average of industry peers (2.8%).
Reported Earnings • May 19First quarter 2022 earnings released: EPS: €0.69 (vs €0.67 in 1Q 2021)First quarter 2022 results: EPS: €0.69 (up from €0.67 in 1Q 2021). Revenue: €239.1m (up 11% from 1Q 2021). Net income: €37.4m (up 2.9% from 1Q 2021). Profit margin: 16% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.8%, compared to a 5.3% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 14Full year 2021 earnings released: EPS: €3.89 (vs €1.59 in FY 2020)Full year 2021 results: EPS: €3.89 (up from €1.59 in FY 2020). Revenue: €960.1m (up 19% from FY 2020). Net income: €209.6m (up 144% from FY 2020). Profit margin: 22% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 10%, compared to a 13% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS €1.15 (vs €0.42 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €264.5m (up 31% from 3Q 2020). Net income: €61.8m (up 173% from 3Q 2020). Profit margin: 23% (up from 11% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Sep 08Second quarter 2021 earnings released: EPS €0.74 (vs €0.22 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €219.1m (up 16% from 2Q 2020). Net income: €39.8m (up 233% from 2Q 2020). Profit margin: 18% (up from 6.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Jun 17Upcoming dividend of €0.88 per shareEligible shareholders must have bought the stock before 24 June 2021. Payment date: 28 June 2021. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (4.0%). Lower than average of industry peers (3.6%).
Reported Earnings • May 21First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €218.0m (up 11% from 1Q 2020). Net income: €36.3m (up 36% from 1Q 2020). Profit margin: 17% (up from 14% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improved over the past weekAfter last week's 21% share price gain to €74.65, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 24x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 89% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €81.84 per share.
Reported Earnings • Apr 16Full year 2020 earnings released: EPS €1.59 (vs €1.43 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €820.5m (up 15% from FY 2019). Net income: €85.8m (up 11% from FY 2019). Profit margin: 11% (in line with FY 2019).
Valuation Update With 7 Day Price Move • Mar 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to €64.69, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 25x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 83% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €81.89 per share.
Is New 90 Day High Low • Feb 05New 90-day high: €60.89The company is up 32% from its price of €46.10 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €67.45 per share.
Is New 90 Day High Low • Dec 29New 90-day high: €57.29The company is up 26% from its price of €45.54 on 30 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €67.08 per share.
Is New 90 Day High Low • Dec 01New 90-day high: €55.96The company is up 22% from its price of €45.82 on 02 September 2020. The British market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €57.89 per share.